07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Buderer Drug, Imprimis deal

Imprimis acquired IP for wound healing product IPI-120, a transdermal formulation of tranexamic acid and an antibiotic, from compounding pharmacy Buderer. Imprimis believes the formulation can reduce or stop bleeding and prevent or treat infection....
07:00 , Jun 24, 2013 |  BC Week In Review  |  Company News

Imprimis, Buderer Drug deal

Imprimis acquired rights to undisclosed IP from compounding pharmacy Buderer and received a right of first refusal for additional IP. Imprimis said the undisclosed IP could lead to up to three development programs. Imprimis said...